Perbak Capital Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Perbak Capital Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,205	Closed	-$931K	–	195
2026 Q1	$931K	Buy	1,205 +891	+284%	+$682K	0.23%	82
2025 Q4	$242K	Sell	314 -1,665	-84%	-$1.13M	0.07%	181
2025 Q3	$1.11M	Buy	1,979 +812	+70%	+$459K	0.2%	111
2025 Q2	$613K	Buy	+1,167	New	+$651K	0.14%	153
2024 Q3	–	Sell	-650	Closed	-$683K	–	51
2024 Q2	$683K	Buy	+650	New	+$630K	0.2%	54

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Perbak Capital Partners's REGN Position: Q2 2026 in Review

Perbak Capital Partners sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 1,205 shares — an estimated $931K sold.

Perbak Capital Partners first reported a position in REGN in Q2 2024 and held it in 5 quarters. The position peaked at $1.11M in Q3 2025. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Perbak Capital Partners reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Perbak Capital Partners sold 1,205 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $931K.
Perbak Capital Partners first reported a position in Regeneron Pharmaceuticals in Q2 2024 and held it in 5 quarters.
Perbak Capital Partners's Regeneron Pharmaceuticals position peaked at $1.11M in Q3 2025.
1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Perbak Capital Partners's 13F filing for Q2 2026.